Loading…
Employees: 172
Size Shouyao Holdings Beijing (688197.SS) is a China Health Care company (Biotechnology) with a market value of $726M, the 2987th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥34.47 on 6 Nov 2026.
Performance Over six months the shares fell 15.6%, against -20.6% for the median peer and -16.4% for the China market (cap-weighted) — 9th highest of 20 in its peer set.
Growth Revenue grew 4,563.9% over the last twelve months (peer median -0.4%); the operating margin is -92.0% (peer median -13.9%).
Valuation It trades at 43.1× enterprise value to sales against a peer median of 4.4× (2nd most expensive of 15).
Capital Return on invested capital runs 83.1 points below its cost of capital (9.7% WACC).
Next results Next results expected around 3 May 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥99.9M | CN¥8.67M | CN¥3.94M | CN¥5.23M | CN¥1.83M |
| Revenue growth | — | +120% | -25% | +186% | — |
| Gross profit | n/a | CN¥620,372 | -CN¥3.29M | -CN¥2.45M | -CN¥4.95M |
| EBITDA | n/a | -CN¥200M | -CN¥225M | -CN¥211M | -CN¥212M |
| Net income | -CN¥18.6M | -CN¥129M | -CN¥212M | -CN¥186M | -CN¥174M |
| Free cash flow | -CN¥119M | -CN¥140M | -CN¥190M | -CN¥183M | -CN¥150M |
| Capital expenditure | CN¥38.3M | CN¥3.20M | CN¥8.57M | CN¥3.83M | CN¥20.7M |
| Total debt | CN¥7.36M | CN¥13.6M | CN¥6.48M | CN¥3.04M | CN¥8.09M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688197.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.8% | -10.5% | 2nd highest of 21 |
| 6-month return | -15.6% | -20.6% | 9th highest of 20 |
| Distance from 52-week high | -25.5% | -41.6% | highest of 21 |
| Revenue growth (TTM) | +4,563.9% | -0.4% | 2nd highest of 14 |
| Operating margin | -92.0% | -13.9% | 6th lowest of 15 |
| EV / Sales | 43.1× | 4.4× | 2nd most expensive of 15 |
| ROIC minus cost of capital | -83.1 pp | -5.1 pp | 2nd lowest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shouyao Holdings Beijing 688197.SS | China | $726M | -16% | +4,564% | -92% | 43.1× | n/a | n/a |
| Sana Biotechnology SANA | United States | $709M | -32% | n/a | n/a | n/a | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $746M | -37% | +153% | -20% | 13.1× | 43.2% | +21.5% |
| Solid Biosciences SLDB | United States | $707M | -9% | n/a | n/a | n/a | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $697M | +744% | n/a | -4,975% | 625.6× | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $688M | -40% | +7% | 3% | 2.1× | n/a | n/a |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $682M | -22% | 0% | 18% | 4.7× | n/a | n/a |
| Aura Biosciences AURA | United States | $680M | -22% | n/a | n/a | n/a | n/a | n/a |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $777M | n/a | n/a | n/a | n/a | n/a | n/a |
| Alphamab Oncology 9966.HK | Hong Kong | $777M | -39% | -32% | -38% | 8.2× | n/a | n/a |
| 4D Molecular Therapeutics FDMT | United States | $677M | +21% | +278,712% | -214% | 3.9× | n/a | n/a |
| Candel Therapeutics CADL | United States | $670M | +5% | n/a | n/a | n/a | n/a | n/a |
| Beijing SL Pharmaceutical 002038.SZ | China | $793M | -21% | -4% | -119% | 7.6× | -12.3% | -10.9% |
| Boji Medical Technology 300404.SZ | China | $664M | +7% | +32% | 4% | 4.1× | 35.4% | +27.2% |
| Wave Life Sciences WVE | United States | $664M | -53% | -35% | -321% | 3.9× | n/a | n/a |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $803M | +91% | -15% | -8% | 17.9× | 48.8% | +14.7% |
| R&G PharmaStudies 301333.SZ | China | $803M | -12% | +21% | 11% | 3.9× | 20.1% | +11.8% |
| Wuhan Keqian Biology 688526.SS | China | $814M | -19% | -22% | 20% | 4.7× | 8.8% | +2.4% |
| Getein Biotech 603387.SS | China | $647M | -12% | +8% | 21% | 2.7× | -8.3% | -1.3% |
| Kura Oncology KURA | United States | $647M | -23% | -7% | -412% | 2.0× | n/a | n/a |
| Design Therapeutics DSGN | United States | $639M | -28% | n/a | n/a | n/a | n/a | n/a |